Most bispecific antibodies (BsAbs) target the subsequent inhibitory receptors on tumor-infiltrating lymphocytes (TILs) with one binding arm while simultaneously blocking the programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) axis with the other to reverse T-cell exhaustion-driven resistance. This evidence concerns the gene PDCD1 and neoplasm.